27 withdrawn. 27 Phase 2, 10 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 27 | Withdrawn 27 |
| Phase 1 | 10 | Withdrawn 10 |
Follow Stomach Diseases: new trials by email Literature Review of Stomach Diseases trials Research Report on Stomach Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma Zimberelimab, Domvanalimab, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel) - Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction | Phase 2 | Withdrawn | Massachusetts General Hospital | 2026-02-01 | 2025-12-26 | |
| INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 Tusamitamab ravtansine - Metastatic Lung Cancer, Metastatic Breast Cancer | Phase 2 | Withdrawn | Erasmus Medical Center | 2024-02-16 | 2024-02-28 | |
| A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors AB-201, Cyclophosphamide, Fludarabine - Breast Cancer, Gastric Cancer | Phase 1 / Phase 2 | Withdrawn | Artiva Biotherapeutics, Inc. | 2023-08-01 | 2025-07-30 | |
| Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss Milademetan, Atezolizumab - Advanced Solid Tumor, CDKN2A | Phase 1 / Phase 2 | Withdrawn | Rain Oncology Inc | 2023-05-19 | 2023-10-19 | |
| EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer EP0057, Olaparib tablets - Gastric Cancer, Small-cell Lung Cancer | Phase 2 | Withdrawn | Ellipses Pharma | 2023-04-01 | 2023-06-12 | |
| TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors TT-4 - Colorectal Cancer, Gastric Cancer | Phase 1 / Phase 2 | Withdrawn | Tarus Therapeutics, Inc. | 2022-12-15 | 2025-03-18 | |
| Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors 1 mg/kg IV FL-301, 3 mg/kg IV FL-301, 10 mg/kg IV FL-301 - Pancreas Cancer, Gastric Cancer | Phase 1 / Phase 2 | Withdrawn | Flame Biosciences | 2022-01-01 | 2022-02-07 | |
| LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery LS301, Cancer Vision Goggles - Pancreatic Cancer, Liver Cancer | Phase 1 / Phase 2 | Withdrawn | Washington University School of Medicine | 2021-12-31 | 2021-12-09 | |
| Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach Apatinib, Oxaliplatin, S1 - Gastric Cancer | Phase 2 | Withdrawn | Peking University | 2021-05-11 | 2025-02-21 | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers SNK01, Trastuzumab, Cetuximab - Advanced Solid Tumor, Metastatic Cancer | Phase 1 / Phase 2 | Withdrawn | NKGen Biotech, Inc. | 2021-03-01 | 2021-05-12 | |
| Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer CEA CAR-T cells - Solid Tumor, Lung Cancer | Phase 1 / Phase 2 | Withdrawn | Chongqing Precision Biotech Co., Ltd | 2020-02-20 | 2026-07-10 | |
| Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) - Gastric Neoplasms | Phase 2 | Withdrawn | University Hospital Tuebingen | 2019-11-01 | 2025-04-03 | |
| An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Relatlimab + Nivolumab, Nivolumab, Paclitaxel - Gastric Cancer, Cancer of the Stomach | Phase 2 | Withdrawn | Bristol-Myers Squibb | 2019-10-31 | 2020-05-19 | |
| Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Trastuzumab, Ramucirumab, Paclitaxel - Gastric Cancer | Phase 2 | Withdrawn | Korean South West Oncology Group | 2019-09-30 | 2019-09-19 | |
| Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis Granisetron - Gastroparesis | Phase 2 | Withdrawn | Indiana University | 2019-01-01 | 2022-02-14 | |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Gastric cancer, Cryotherapy - Advanced Gastric Cancer | Phase 2 | Withdrawn | Fuda Cancer Hospital, Guangzhou | 2018-04-05 | 2020-10-19 | |
| A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach mFLOFOX6 + pembrolizumab - Adenocarcinoma, Stomach Cancer | Phase 2 | Withdrawn | Weijing Sun, MD, FACP | 2017-01-01 | 2018-07-13 | |
| Naloxegol for Opioid-Related Gastroparesis Naloxegol 25 MG Oral Tablet [Movantik], Placebo Oral Tablet - Gastroparesis, Opioid Use | Phase 2 | Withdrawn | Temple University | 2016-12-29 | 2020-08-27 | |
| A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer Anti-HER2 CAR-T - Breast Cancer, Ovarian Cancer | Phase 1 / Phase 2 | Withdrawn | Zhi Yang | 2016-03-01 | 2020-03-19 | |
| C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer c-Met inhibitor AMG 337, placebo, oxaliplatin - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Withdrawn | Eastern Cooperative Oncology Group | 2015-03-06 | 2023-05-25 |
Showing 20 of 27. Sign in to see all of them.
Stomach Neoplasms (25) · Breast Neoplasms (6) · Pancreatic Neoplasms (6) · Colorectal Neoplasms (4) · Lung Neoplasms (4) · Esophageal Neoplasms (3) · Neoplasm Metastasis (3) · Ovarian Neoplasms (3) · Adenocarcinoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Gastroparesis (2) · Head and Neck Neoplasms (2) · Liver Neoplasms (2) · Recurrence (2) · Small Cell Lung Carcinoma (2)
Digestive System Diseases (27) · Gastrointestinal Diseases (27) · Digestive System Neoplasms (25) · Neoplasms by Site (25) · Gastrointestinal Neoplasms (24) · Neoplasms (24) · Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7) · Neoplasms by Histologic Type (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Breast Diseases (6) · Lung Diseases (6) · Neoplasms, Glandular and Epithelial (6)
Oxaliplatin (3) · Paclitaxel (3) · Irinotecan (2) · Ramucirumab (2) · Trastuzumab (2) · 4-phenylbutyric acid (1) · AMG 337 (1) · ARQ 197 (1) · Biopsy (1) · Capecitabine (1) · Cetuximab (1) · Cryotherapy (1) · Cyclophosphamide (1) · Cyclosporins (1) · Fluorometholone (1)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (1) · Artiva Biotherapeutics, Inc. (1) · Bristol-Myers Squibb (1) · Chongqing Precision Biotech Co., Ltd (1) · Eastern Cooperative Oncology Group (1) · Ellipses Pharma (1) · Erasmus Medical Center (1) · Flame Biosciences (1) · Fuda Cancer Hospital, Guangzhou (1) · Hokkaido Gastrointestinal Cancer Study Group (1) · ImmunoGen, Inc. (1) · Indiana University (1) · Korean South West Oncology Group (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1)
United States (9) · China (5) · South Korea (3) · Germany (2) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · Chile (1) · Colombia (1) · Italy (1) · Japan (1) · Mexico (1) · Netherlands (1) · Portugal (1)
Bita Esmaeli, MD (1) · Cassandra Choe-Juliak, MD (1) · Cheng Qian, MD,PhD (1) · Debbie Robbrecht, Dr. (1) · Eun-Kee Song (1) · Frank Lanza, MD (1) · Henry Parkman, MD (1) · Jibing Chen, Doctor (1) · John M Wo, MD (1) · Kuno Lehmann, MD (1) · Lakshmi Rajdev (1) · Masahiro Asaka, MD, PhD (1) · Paul Y. Song, MD (1) · Ryan C Fields, M.D. (1)
2018 (1), U10CA180820 (1)